Eritel 40 Tablet contains Telmisartan 40 mg, an angiotensin II receptor antagonist primarily prescribed for the management of hypertension. By selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, Telmisartan promotes vasodilation, thereby reducing peripheral vascular resistance and lowering blood pressure. This antihypertensive action helps prevent complications associated with high blood pressure, including stroke, myocardial infarction, and renal impairment. Eritel 40 is indicated for the treatment of essential hypertension and may be used alone or in combination with other antihypertensive agents. Additionally, Telmisartan has demonstrated benefits in reducing cardiovascular morbidity in patients at high risk, such as those with left ventricular hypertrophy or type 2 diabetes with end-organ damage. The tablet is generally well-tolerated; however, potential adverse effects include dizziness, hypotension, hyperkalemia, and renal function alterations. It is contraindicated in patients with hypersensitivity to Telmisartan or any tablet components, and caution is advised in individuals with renal artery stenosis or severe hepatic impairment. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Eritel 40 should be used under medical supervision, adhering to prescribed dosage to optimize therapeutic outcomes and minimize risks.